Betahistine
- Generic Name
- Betahistine
- Brand Names
- Serc
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N2
- CAS Number
- 5638-76-6
- Unique Ingredient Identifier
- X32KK4201D
- Background
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.
Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to reduce symptoms through its actions on histamine receptors. Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.
- Indication
Betahistine is indicated for the reduction of recurrent vertigo episodes associated with Ménière's disease in patients 18 years old and above.
- Associated Conditions
- Menière's Disease
- Associated Therapies
- -
The Effect of Betahistine on Body Weight in Obese Subjects
- Conditions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- OBEcure Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT00409305
- Locations
- 🇺🇸
Scripps Clinic, Nutrition Metabolic Research, San Diego, California, United States
🇺🇸Rochester Clinical Research, Inc., Rochester, New York, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.